Sponsor
CASI pharmaceuticals, Inc.
Clinical research sponsor
How to interpret these research links
Connected source recordsThe exact organization name CASI pharmaceuticals, Inc. appears in 5 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
5 shownPhase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBCNCT01639248 · lead sponsor · 2012-07-01
COMPLETEDEfficacy and Pharmacodynamic Study of Panzem® NCD in Patients With Hormone-Refractory Prostate CancerNCT00394810 · lead sponsor · 2006-11-01
COMPLETEDSafety Study of MKC-1 Combined With Pemetrexed to Treat Advanced Cancer and Non-Small Cell Lung CancerNCT00408226 · lead sponsor · 2006-10-01
COMPLETEDA Study to Determine the Antitumor Activity and Evaluate the Safety of MKC-1NCT00306631 · lead sponsor · 2006-01-01
COMPLETEDSafety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung CancerNCT00049790 · lead sponsor
COMPLETEDSponsor roles
lead sponsor5
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.